Recombinant Mouse IFN-alpha/beta R2 Fc Chimera Protein, CF

Recombinant Mouse IFN-alpha/beta R2 Fc Chimera Protein, CF Summary

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: IFN-alpha/beta R2

IFN‑ alpha / beta  R2, also known as IFNAR2, is a 100 kDa glycoprotein member of the class II cytokine receptor family. Proteins from this family form heterodimeric receptor complexes that transduce signals from the type I and II interferon, Tissue factor, IL‑10, and IL‑28/IFN‑ lambda families of cytokines (1‑3). IFN‑ alpha / beta  R2, in association with IFN‑ alpha / beta  R1, is required for mediating the antiviral, antiproliferative, and apoptotic effects of the type I interferons IFN‑ alpha and IFN‑ beta. IFN‑ alpha / beta R2 is the high‑affinity ligand binding subunit of the receptor. Ligand binding is stabilized by the subsequent association with IFN‑ alpha / beta  R1, resulting in the formation of a signaling ternary receptor complex (4, 5). Mature mouse IFN‑ alpha / beta  R2 consists of a 221 aa extracellular domain (ECD) with two fibronectin type III repeats, a 21 aa transmembrane segment, and a 250 aa cytoplasmic domain. Alternate splicing generates an approximately 45 kDa secreted isoform that corresponds to the ECD (6, 7). Human IFN‑ alpha / beta  R2 is also subject to presenilin‑dependent intramembrane proteolysis, resulting in the liberation of nearly the entire ECD as well as the cytoplasmic domain which migrates to the nucleus and can inhibit gene transcription (8). High concentrations of soluble IFN‑ alpha / beta  R2 bind and neutralize IFN‑ alpha and IFN‑ beta, while lower concentrations prolong the antiviral activity of circulating IFN‑ beta but not IFN‑ alpha (9, 10). Complexes of the soluble receptor with IFN‑ alpha or IFN‑ beta can also exert agonistic activity in cells that lack IFN‑ alpha / beta  R2 (10). Human, but not mouse, IFN‑ alpha / beta  R2 constitutively associates with STAT4, which may account for species specific differences observed in type I interferon responses (11). Within the ECD, mouse IFN‑ alpha / beta  R2 shares 46% and 67% aa sequence identity with human and rat IFN‑ alpha / beta  R2, respectively.

Related Research Areas

• Cytokines and Receptors in Angiogenesis
• Interferons
• Receptors in the Jak/STAT Pathway